


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

1. (Currently Amended) A compound of the Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof wherein:


A is aryl optionally substituted with at least one R¹ group, heteroaryl, C₁-C₆alkenyl, C₁-C₆alkynyl, CN, halo, COOH, C(O)NR⁴R⁵, NRR', N(R')S(O)₂R, N(R')C(O)R, or N(R')C(O)NR⁴R⁵,

R¹ is C₁-C₆alkyl, aryl, C₁-C₆alkoxy, aryloxy, halo, -COOH, -CN, -S(O)₂NR⁴R⁵, -S(O)₂R, -C(O)NR⁴R⁵, -NRR', -N(H)C(O)NR⁴R⁵, -O(CH₂)_nCOOH, -(CH₂)_nCOOH, -C(O)O(CH₂)_nR, -(CH₂)_nN(H)C(O)OR, or -N(R')S(O)₂R;

R is -H, C₁-C₆alkyl, aryl, or heteroaryl;

R' is -H or C₁-C₃alkyl;

D is selected from the group consisting of:



R² is -H, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, aryl, heteroaryl, -S(O)₂NR⁴R⁵, -COOH, -C(O)OR⁶, -C(O)NR⁴R⁵, NRR', -N(H)C(O)NRR', -N(H)C(O)R, or -N(H)S(O)₂R;
q is 1, 2, 3, or 4;

R³ is -H, C₁-C₃ alkyl, aryl, aralkyl, or heteroaryl;

R⁴ is -H or C₁-C₃ alkyl;

R⁵ is -H or C₁-C₃ alkyl; or

R⁴ and R⁵ together with the nitrogen to which they are attached form a heterocycl ring, said ring optionally containing 1 or 2 additional oxygen, S(O)_m, or nitrogen atoms; said nitrogen atoms being optionally substituted by a C₁-C₃ alkyl group;

m is 0, 1, or 2; and


R⁶ is C₁-C₆ alkyl.

2 – 6. (Cancelled)

7. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and one or more of pharmaceutically acceptable carriers, diluents and excipients.

8. (Cancelled)

9. (Currently Amended) The compound of claim 1_8, wherein D is:



10 – 13. (Cancelled)

14. (Currently Amended) A The compound of claim 1, wherein said compound is selected from the group consisting of:

~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;~~
~~5-bromo-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;~~
~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-phenylpyrazin-2-amine;~~
~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(3,4,5-trimethoxyphenyl)pyrazin-2-amine;~~
~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-fluorophenyl)pyrazin-2-amine;~~
~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-thien-2-ylpyrazin-2-amine;~~
~~5-(4-aminophenyl)-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;~~
~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-pyridin-3-ylpyrazin-2-amine;~~
~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-indol-5-yl)pyrazin-2-amine;~~
~~3-[1-(2-methoxyethyl)-1H-benzimidazol-2-yl]-5-thien-2-ylpyrazin-2-amine;~~
~~3-(1H-benzimidazol-2-yl)-5-(3-fluorophenyl)pyrazin-2-amine;~~
~~3-(1H-benzimidazol-2-yl)-5-(4-fluorophenyl)pyrazin-2-amine;~~
4-[5-amino-6-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]-N,N-dimethylbenzenesulfonamide;
3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-[3-(methylsulfonyl)phenyl]pyrazin-2-amine;

3-{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenyl}propanoic acid;

{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenoxy}acetic acid;

{3-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenoxy}acetic acid;

N-{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenyl}methanesulfonamide;

benzyl 4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]benzoate;

5-[4-(benzyloxy)phenyl]-3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

5-[1,1'-biphenyl-3-yl)-3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]benzoic acid;

tert-butyl 3-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]
benzylcabamatebenzylcarbamate;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrrol-2-yl)pyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-indol-2-yl)pyrazin-2-amine; and

5-[(4-aminophenyl)ethynyl]-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

or a salt, solvate, or physiologically functional derivative thereof.

15. (Cancelled)